SARS-CoV-2 - Deferoxamine - Therapeutic Candidates

SARS-CoV-2 - Deferoxamine - Therapeutic Candidates


Deferoxamine (or Desferal) is a linear bacterial siderophore and chelating agent for trivalent cations. Deferoxamine is capable of binding free iron from plasma or cells to form the ferrioxamine complex. Due to its properties, deferoxamine is used as a first-line treatment for iron overload. Desferal is prescribed for various pathologies such as primary hemochromatosis, secondary hemosiderosis, acute martial intoxication, aluminum poisoning.
Deferoxamine has been included in some clinical studies to develop a treatment for COVID-19 caused by the SARS-CoV-2 coronavirus. Indeed, studies have shown that the replication of some RNA viruses, such as HIV-1 or cytomegalovirus, can be influenced by iron. Deferoxamine was able to inhibit viral replication in cells in vitro. For this reason, deferoxamine is being tested as part of the development of a treatment for COVID-19.

Search result : 65 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 6
  • Biochemicals 54
  • Inhibitor/Antagonist/Agonist 11
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
NB-42-00669-5g
 5g 
NB-42-00669-10g
 10g 
HY-B0988-100mg
 100mg 
T1637-200mg
 200mg 
T1637-100mg
 100mg 
T1637-500mg
 500mg 
HY-B0988-1ml
 10mM/1mL 
445960-5mg
 5mg 
445960-1mg
 1mg 
331-21718-2
 500mg 
AG007ZDX-100mg
 100mg 
331-21718-1
 100mg 
AG007ZDX-250mg
 250mg 
AG007ZDX-1g
 1g 
AG007ZDX-5g
 5g 
271301-500mg
 500mg 
458230-1mg
 1mg